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The RACE-3 is on: double-locking sinus rhythm
by upstream and downstream therapy
Davor Pavlovic1, Paulus Kirchhof1,2,3, and Larissa Fabritz1,3*
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This editorial refers to ‘Targeted therapy of underlying con-
ditions improves sinus rhythm maintenance in patients
with persistent atrial fibrillation: results of the RACE 3
trial’, byM. Rienstra et al. doi:10.1093/eurheartj/ehx739.
Recent advances in the field of anticoagulation have given us powerful
tools to reduce stroke and its associated disease burden in patients
with atrial fibrillation.1–4 More work needs to be done to offer ad-
equate anticoagulation to all patients with atrial fibrillation at risk for
stroke,5,6 and ongoing trials explore the limits of anticoagulation in
patients with very low levels of atrial arrhythmias.7,8 However, even
in adequately anticoagulated patients with atrial fibrillation, important
unmet therapeutic needs remain, particularly around prevention
of sudden death, heart failure, and unplanned cardiovascular
hospitalizations.5
Many groups have speculated that ‘upstream therapy’ or ‘prevention
of atrial remodelling’ can improve rhythm control therapy in patients
with atrial fibrillation.9,10 Clinical trials conducted so far have not con-
clusively demonstrated effectiveness of either angiotensin-converting
enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), or
statins in reducing recurrent AF.11–13 In this issue of the journal, van
Gelder and colleagues report the outcome of the RACE-3 study.14
RACE-3 tested whether the addition of a comprehensive ‘upstream
therapy’ package, consisting of mineralocorticoid receptor antagonists
(MRAs), statins, ACE-Is and/or ARBs, and cardiac rehabilitation includ-
ing physical activity, dietary restrictions, and counselling, improves sinus
rhythm maintenance in anticoagulated patients with persistent atrial
fibrillation undergoing rhythm control therapy.9 This elegant design
combines several important components of ‘upstream therapy’ into a
single intervention, thus quantifying the positive effect of ‘upstream
therapy’ in its totality for recurrent atrial fibrillation in 1 year.15
In RACE-3, patients randomized to the ‘upstream therapy’ interven-
tion had lower blood lipid levels, lower levels of brain natriuretic pep-
tide (BNP), and lower blood pressure than the control group at follow
up, demonstrating that the intervention had the desired biological
effects. The feasibility of an intervention to reduce the cardiovascular
risk profile in patients with atrial fibrillation is an important finding in it-
self and should empower primary and secondary prevention initiatives.
The authors found a slightly higher number of patients in sinus rhythm
after 1 year, with a nominally significant P-value (P = 0.04) in the pri-
mary outcome of the study, defined as sinus rhythm on at least 6 out
of 7 days of a 7 day Holter ECG at 1 year follow-up. Other rhythm
outcomes were not different between groups, e.g. the number of re-
peat cardioversions, the time to recurrent atrial fibrillation, or cardio-
vascular hospitalizations. This may be due to the weaker long-term and
indirect effects of the intervention on atrial electrical function (Take
home figure) which contrasts with the immediate direct effects of anti-
arrhythmic drugs and ablation procedures. Of note, the use of ACE-Is/
ARBs was high in both study groups, and catheter ablation was rarely
used in the study population, with only seven ablations performed.
The results illustrate two main points: (i) a comprehensive ‘up-
stream therapy’ treatment package in patients with persistent atrial
fibrillation and some degree of heart failure only slightly improves
prevention of recurrent AF in the short term; and (ii) such treatment
seems safe and leads to desirable reductions in lipid profiles, BNP,
and blood pressure.
What does the study add?
Like every well-designed study, RACE-3 provides important answers
and raises new questions. MRAs, statins, ACE-Is/ARBs, and cardiac re-
habilitation improved important surrogates for cardiovascular out-
comes without major safety concerns. As such, the study results
demonstrate the feasibility of comprehensive cardiovascular risk reduc-
tion in patients with atrial fibrillation, supporting the concept of inte-
grated care for these patients,1,5,6 as the authors discuss elegantly.14
RACE-3 also illustrates the limited short-term effectiveness of ‘up-
stream therapy’ for preventing recurrent atrial fibrillation after
cardioversion: even a comprehensive package tackling underlying
cardiovascular conditions by rehabilitation, statins, MRAs, and renin–
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..angiotensin–aldosterone system (RAAS) inhibition did not affect the
number of repeat cardioversions, time to recurrent atrial fibrillation,
or cardiovascular hospitalizations. More efficient weight loss strategies
could possibly also lead to better outcomes in the future, as there was
only a slight decrease in body mass index in the intervention group in
RACE-3. Longer term assessment of the intervention tested in RACE-
3 may provide further benefits to the patients as the ‘upstream ther-
apy’ package may have more pronounced effects on atrial fibrillation
after several years of treatment. We look ahead for the long-term fol-
low-up of this patient cohort for answers to these questions.
What does that mean for clinical
practice?
MRA inhibition, RAAS inhibition, and statins should be considered in
patients with persistent atrial fibrillation as part of an integrated ap-
proach to the care of patients with atrial fibrillation.5,6 The results
also illustrate that the effect of ‘upstream therapy’ on recurrent atrial
fibrillation in patients with persistent atrial fibrillation is modest at
best, and clearly weaker than the short-term effect of antiarrhythmic
drug therapy or catheter ablation.21,22 Testing the effectiveness of
‘upstream therapy’ over a longer time frame may still demonstrate
that such treatments lead to better outcomes. Nevertheless, tar-
geted and direct treatment of electrical drivers of AF is needed to im-
prove rhythm control therapy, e.g. early rhythm control
interventions,18,23 hybrid therapy incorporating catheter ablation and
antiarrhythmic drugs,1,16,17 and treatment approaches based on the
major drivers of atrial fibrillation (Take home figure).15
More upstream and downstream
work is needed
The results of RACE-3 illustrate that risk factor management cannot
replace direct treatment of the electrical drivers of atrial fibrillation
by antiarrhythmic drugs and catheter ablation (Take home figure).
While we await the full publication of the CASTLE-AF trial outcome,
the next few years should provide new information on the role of
modern and comprehensive rhythm control therapy for cardiovascu-
lar outcomes in patients with atrial fibrillation.16–18 In addition, there
is a clear need to improve rate control therapy to avoid worsening of
heart failure in patients with atrial fibrillation, including mechanistic
work to identify patients who benefit from specific treatments.19,20
Clearly, the road to successful maintenance of sinus rhythm re-
quires careful consideration of the major health modifiers causing
atrial fibrillation. A substantial body of evidence demonstrates that
atrial fibrillation and other underlying cardiovascular conditions alter
structural and electrical properties of the atria,10,15 including intersti-
tial fibrosis, increased formation of extracellular matrix, alterations in
cell–cell contact proteins, adipose tissue activation and infiltration,
changes in gene expression pattern, oxidative stress, calcium abnor-
malities, and others. Dysregulation of the RAAS and autonomic dys-
function are found in atrial fibrillation, hypertension, heart failure,
Take home ﬁgure Illustration of major upstream and downstream drivers of atrial fibrillation (AF) and direct and indirect links to cardiovascu-
lar outcomes. Upstream therapy targets major indirect drivers of AF, including high blood pressure, renin-angiotensin-aldosterone-system (RAAS)
activation, reactive oxygen species (ROS), increased sodium load, dyslipoproteinaemia and epicardial fat. Upstream therapy thus also reduces atrial
load and strain, fibrosis and fat infiltration in the atria. Rhythm control therapy directly targets triggered activity, action potential duration (APD)
shortening and slowed conduction across the atria. Inset; atrial electrical function can be altered by fatty deposition (shown in yellow) and interstitial
fibrosis (shown in red). Dashed lines indicate less established links, solid lines established links to a delta of cardiovascular complications. ICV, inferior
caval vein; LA, left atrium; LPV, left pulmonary vein; RA, right atrium; SAN, sinoatrial node.
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kidney dysfunction, or obesity, and further promote atrial remodel-
ling. Early-onset atrial fibrillation in particular can be driven by a gen-
etic or genomic component that must also be taken into
consideration during treatment. Attenuation of such complex patho-
physiological stimuli requires a collaborative effort of basic and clin-
ical arms of our research, if we are to tackle the ever-increasing
incidence and prevalence of atrial fibrillation.
The double lock
Joint upstream and downstream therapy can provide a double lock
to slow progression of the atrial fibrillation, but more work needs to
be done. The results of RACE-3 thus call for a full-scale effort
to tighten rhythm control therapy upstream and downstream,
considering the major drivers of recurrent atrial fibrillation in patients
by stratified therapy.
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